Canada - English - Health Canada

exclusive products inc. - alkyl dimethyl ethylbenzyl ammonium chloride; benzalkonium chloride - spray - 0.15%; 0.15% - alkyl dimethyl ethylbenzyl ammonium chloride 0.15%; benzalkonium chloride 0.15% - disinfectants (for agents used on object)

New Zealand - English - Medsafe (Medicines Safety Authority)

upjohn new zealand ulc - alprazolam 0.25mg (exclusive of 1.5% excess.);  ;   - tablet - 0.25 mg - active: alprazolam 0.25mg (exclusive of 1.5% excess.)     excipient: colloidal silicon dioxide [docusate sodium (85% ) with sodium benzoate [15%] lactose monohydrate magnesium stearate maize starch microcrystalline cellulose - 1. anxiety states (anxiety neuroses). symptoms which occur in such patients include anxiety, tension, fear, insomnia, apprehension, restlessness, concentration difficulties, irritability and/or autonomic hyperactivity resulting in a variety of somatic complaints. 2. mixed anxiety-depression. symptoms of both anxiety and depression occur concurrently in such patients. 3. neurotic or reactive depression. such patients primarily exhibit a depressed mood or a pervasive loss of interest or pleasure. other characteristics include anxiety, appetite disturbances, changes in weight, cognitive disturbances, decreased energy, feeling of worthlessness or guilt, insomnia, somatic complaints, or thoughts of death or suicide. 4. anxiety states, mixed anxiety-depression, or neurotic depression associated with other diseases such as the chronic phase of alcohol withdrawal and functional or organic disease, particularly certain gastrointestinal, cardiovascular, or dermatological disorders.

New Zealand - English - Medsafe (Medicines Safety Authority)

upjohn new zealand ulc - alprazolam 0.5mg (exclusive of 1.5% excess.);  ;   - tablet - 0.5 mg - active: alprazolam 0.5mg (exclusive of 1.5% excess.)     excipient: colloidal silicon dioxide docusate sodium erythrosine lactose monohydrate magnesium stearate maize starch microcrystalline cellulose sodium benzoate - 1. anxiety states (anxiety neuroses). symptoms which occur in such patients include anxiety, tension, fear, insomnia, apprehension, restlessness, concentration difficulties, irritability and/or autonomic hyperactivity resulting in a variety of somatic complaints. 2. mixed anxiety-depression. symptoms of both anxiety and depression occur concurrently in such patients. 3. neurotic or reactive depression. such patients primarily exhibit a depressed mood or a pervasive loss of interest or pleasure. other characteristics include anxiety, appetite disturbances, changes in weight, cognitive disturbances, decreased energy, feeling of worthlessness or guilt, insomnia, somatic complaints, or thoughts of death or suicide. 4. anxiety states, mixed anxiety-depression, or neurotic depression associated with other diseases such as the chronic phase of alcohol withdrawal and functional or organic disease, particularly certain gastrointestinal, cardiovascular, or dermatological disorders.

New Zealand - English - Medsafe (Medicines Safety Authority)

upjohn new zealand ulc - alprazolam 1mg (exclusive of 1.5% excess.);  ;   - tablet - 1 mg - active: alprazolam 1mg (exclusive of 1.5% excess.)     excipient: colloidal silicon dioxide erythrosine indigo carmine docusate sodium (85%) with sodium benzoate (15%) lactose monohydrate magnesium stearate maize starch microcrystalline cellulose - 1. anxiety states (anxiety neuroses). symptoms which occur in such patients include anxiety, tension, fear, insomnia, apprehension, restlessness, concentration difficulties, irritability and/or autonomic hyperactivity resulting in a variety of somatic complaints. 2. mixed anxiety-depression. symptoms of both anxiety and depression occur concurrently in such patients. 3. neurotic or reactive depression. such patients primarily exhibit a depressed mood or a pervasive loss of interest or pleasure. other characteristics include anxiety, appetite disturbances, changes in weight, cognitive disturbances, decreased energy, feeling of worthlessness or guilt, insomnia, somatic complaints, or thoughts of death or suicide. 4. anxiety states, mixed anxiety-depression, or neurotic depression associated with other diseases such as the chronic phase of alcohol withdrawal and functional or organic disease, particularly certain gastrointestinal, cardiovascular, or dermatological disorders.

United States - English - NLM (National Library of Medicine)

tat kimya sabun ve gliserin sanayi ve ticaret anonim sirketi - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - antiseptic, hand sanitizer hand sanitizer to help reduce bacteria that potentially can cause disease. for use when soap and water are not available. - in children less than 2 months of age - on open skin wounds stop use and ask a doctor if irritation or rash occurs. these may be signs of a serious condition.

India - English - Central Drugs Standard Control Organization

cfl ph. - tab - 10

India - English - Central Drugs Standard Control Organization

cfl ph. - d.syr - 30ml

India - English - Central Drugs Standard Control Organization

cfl ph. - tab - 10

India - English - Central Drugs Standard Control Organization

cfl ph. - tab - 10

India - English - Central Drugs Standard Control Organization

cfl ph. - tab - 10